The University of Siena PhD Course in
Genetics, Oncology and Clinical Medicine


PhD Graduate

Raffaele LA MONTAGNA 

PhD Program years: 2007 - 2011







PUBLICATIONS DURING THE PHD PROGRAM
  1. Scope and limitations of the designer proline-rich antibacterial peptide dimer, A3-APO, alone or in synergy with conventional antibiotics.
    Cassone M, Vogiatzi P, La Montagna R, De Olivier Inacio V, Cudic P, Wade JD, Otvos L Jr.
    Peptides. 2008 Nov;29(11):1878-86.

  2. Leptin signaling in breast cancer: an overview.
    Cirillo D, Rachiglio AM, la Montagna R, Giordano A, Normanno N.
    J Cell Biochem. 2008 Nov 1;105(4):956-64. Review

  3. The antiretroviral nucleoside analogue Abacavir reduces cell growth and promotes differentiation of human medulloblastoma cells.
    Rossi A, Russo G, Puca A, La Montagna R, Caputo M, Mattioli E, Lopez M, Giordano A, Pentimalli F.
    Int J Cancer. 2009 Jul 1;125(1):235-43.

  4. New pyrazolo-[3,4-d]-pyrimidine derivative Src kinase inhibitors lead to cell cycle arrest and tumor growth reduction of human medulloblastoma cells.
    Rossi A, Schenone S, Angelucci A, Cozzi M, Caracciolo V, Pentimalli F, Puca A, Pucci B, La Montagna R, Bologna M, Botta M, Giordano A.
    FASEB J. 2010 Aug;24(8):2881-92. Epub 2010 Mar 30.

  5. Adenosine receptor ligands in clinical trials.
    Rizzolio F, La Montagna R, Tuccinardi T, Russo G, Caputi M, Giordano A.
    Curr Top Med Chem. 2010;10(10):1036-45. 
ABSTRACTS OF CONFERENCE DURING THE PHD PROGRAM

PIN1 forms a protein complex with Rb2/p130 and controls its phosphorylation status (101st Annual Meeting American Association for Cancer Research, Washington, USA, 17-21/4/2010)

ACTIVITY DURING THE PHD PROGRAM

TRAINING PERIOD ABROAD
    Sbarro Institute for Cancer Research and Molecular Medicine, Center for Biotechnology, College of Science and Technology, Temple University, Philadelphia, Pennsylvania, USA
    2010: twelve months